PofoliaShared via Pofolia

Journal of Clinical Oncology· 2012Q1· Clinical trial

Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer

Arlene A. Forastiere, Qiang Zhang, Randal S. Weber, Moshe Maor et al.

Short summary

Adding chemotherapy to radiation therapy significantly improved larynx preservation rates in locally advanced larynx cancer patients compared to radiation alone, with concomitant chemotherapy showing superior larynx preservation over induction chemotherapy.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Concomitant cisplatin/RT significantly improved larynx preservation rates (HR 0.58 vs. induction, P=.0050; HR <0.33 vs. RT alone, P<.001).
  • Both induction and concomitant chemotherapy regimens improved laryngectomy-free survival (LFS) compared to RT alone (HR 0.75 and 0.78, respectively; P=.02 and P=.03).
  • Overall survival did not differ significantly between treatment arms.
  • Deaths not attributed to larynx cancer or treatment were higher with concomitant chemotherapy (30.8%) compared to induction chemotherapy (20.8%) and RT alone (16.9%).

AI-generated from the title and abstract; the full text is not read.

Abstract

PURPOSE: To report the long-term results of the Intergroup Radiation Therapy Oncology Group 91-11 study evaluating the contribution of chemotherapy added to radiation therapy (RT) for larynx preservation. PATIENTS AND METHODS: Patients with stage III or IV glottic or supraglottic squamous cell cancer were randomly assigned to induction cisplatin/fluorouracil (PF) followed by RT (control arm), concomitant cisplatin/RT, or RT alone. The composite end point of laryngectomy-free survival (LFS) was the primary end point. RESULTS: Five hundred twenty patients were analyzed. Median follow-up for surviving patients is 10.8 years. Both chemotherapy regimens significantly improved LFS compared with RT alone (induction chemotherapy v RT alone: hazard ratio [HR], 0.75; 95% CI, 0.59 to 0.95; P = .02; concomitant chemotherapy v RT alone: HR, 0.78; 95% CI, 0.78 to 0.98; P = .03). Overall survival did not differ significantly, although there was a possibility of worse outcome with concomitant relative to induction chemotherapy (HR, 1.25; 95% CI, 0.98 to 1.61; P = .08). Concomitant cisplatin/RT significantly improved the larynx preservation rate over induction PF followed by RT (HR, 0.58; 95% CI, 0.37 to 0.89; P = .0050) and over RT alone (P < .001), whereas induction PF followed by RT was not better than treatment with RT alone (HR, 1.26; 95% CI, 0.88 to 1.82; P = .35). No difference in late effects was detected, but deaths not attributed to larynx cancer or treatment were higher with concomitant chemotherapy (30.8% v 20.8% with induction chemotherapy and 16.9% with RT alone). CONCLUSION: These 10-year results show that induction PF followed by RT and concomitant cisplatin/RT show similar efficacy for the composite end point of LFS. Locoregional control and larynx preservation were significantly improved with concomitant cisplatin/RT compared with the induction arm or RT alone. New strategies that improve organ preservation and function with less morbidity are needed.

The authors' abstract, as published at the source. Journal of Clinical Oncology, 2012 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Otorhinolaryngology

OtorhinolaryngologyMedicine